Vidostream | News, sport and opinion from the Vidostream's US edition

https://vidostream.com

U.S. scientist says he was demoted for raising red flags over unproven COVID-19 treatment

Whistleblower complaint says he resisted pressure to push drug favoured by Trump administration
A U.S. government scientist has filed a complaint saying he was demoted for raising concerns about the use of hydroxychloroquine to treat COVID-19. (John Locher/The Associated Press)

A U.S. government scientist has filed a complaint saying he was demoted for raising concerns about the use of hydroxychloroquine to treat COVID-19. (John Locher/The Associated Press)

A U.S. government scientist says he was ousted from his position after raising concerns the Trump administration wanted to "flood" coronavirus hot spots such as New York and New Jersey with a malaria drug despite scant scientific evidence it is effective against COVID-19.

Rick Bright, former director of the Biomedical Advanced Research and Development Authority, filed the complaint Tuesday with the Office of Special Counsel, a government agency responsible for whistleblower complaints.

He alleges he was reassigned to a lesser role because he resisted political pressure to allow widespread use of hydroxychloroquine, a malaria drug touted publicly by President Donald Trump.

Bright also said the Trump administration rejected his warnings on COVID-19, the disease caused by the virus. Bright said he "acted with urgency" to address the growing spread of COVID-19 after the World Health Organization (WHO) issued a warning in January.

He said he "encountered resistance from HHS leadership, including Health and Human Services Secretary Alex Azar, who appeared intent on downplaying this catastrophic event."

Bright alleges in the complaint that political appointees at the Department of Health and Human Services had tried to promote hydroxychloroquine "as a panacea." The officials also "demanded that New York and New Jersey be 'flooded' with these drugs, which were imported from factories in Pakistan and India that had not been inspected by the FDA," the complaint says.

Serious side-effects

But Bright says he opposed broad use of the drug to treat COVID-19 patients, arguing the scientific evidence wasn't there to back up such a course of action. He felt an urgent need to tell the public as much, the complaint states.

Last month, the U.S. Food and Drug Administration warned doctors against prescribing the drug except in hospitals and research studies. In an alert, regulators flagged reports of sometimes fatal heart side-effects among COVID-19 patients taking hydroxychloroquine or the related drug chloroquine.

The decades-old drugs, also prescribed for lupus and rheumatoid arthritis, can cause a number of side-effects, including heart rhythm problems, severely low blood pressure and muscle or nerve damage.

The complaint says officials to whom Bright had complained "refused to listen or take appropriate action to accurately inform the public" and so he spoke to a reporter who was working on a story about the drug.

"As the death toll mounted exponentially each day, Dr. Bright concluded that he had a moral obligation to the American public, including those vulnerable as a result of illness from COVID-19, to protect it from drugs which he believed constituted a substantial and specific danger to public health and safety," the complaint says.

On Jan. 20, according to the complaint, the WHO held an emergency call to discuss the novel coronavirus. It was attended by many HHS officials, and WHO officials advised that "the outbreak is a big problem."

Trump has accused the UN agency of mismanaging and covering up the spread of the virus after it emerged in China and said he would cut its funding.

In the complaint, Bright says he wants to be returned to his position as director of the Biomedical Advanced Research and Development Authority and a full investigation launched.

A spokeswoman for HHS has said it was Bright who had requested an emergency use authorization for chloroquine and hydroxychloroquine. For his part, Bright said he had insisted that the authorization be limited to a restricted group of patients, those hospitalized with confirmed COVID-19 under the supervision of a doctor.

Source: CBC News:

We are using cookies to give you the best experience on our website. By continuing to browse, you are agreeing to our Cookie Policy.
You did not use the site, Click here to remain logged. Timeout: 60 second